2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

655. Multiple Myeloma: Cellular Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Systems-Based Hematology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

5809 Risk scores to predict CAR-T and bispecific antibody outcomes in multiple myeloma at the time of evaluation

Christoph Schaefers, MD, Nicholas Jeffrey Braun, PhD2, Jonas Paludo, MD3, Melinda Tan, MD4, Katharine Dooley, MPH5, Andre De Menezes Silva Corraes, MD6, Malvika Gupta, MD7, Ricardo Daniel Parrondo, MD8, Morie Gertz9, Prashant Kapoor, MD10, Taxiarchis Kourelis, MD11, Rahma Warsame, MD12, Joselle M Cook, M.D.13, Nadine Abdallah I, MD14, Moritz Binder, MD, MPH15, Wilson Gonsalves, MD16, Nelson Leung, MD17, Rafael Fonseca, MD18, P. Leif Bergsagel, MD19, Udit Yadav, MBBS20, J Erin Wiedmeier-Nutor, MD,MPH21, Shaji Kumar, MD22, Susan Geyer, PhD23, Saurabh Chhabra, MD, MBBS24, Sikander Ailawadhi, MD25, Saurabh Zanwar, MBBS, MD26, Yi Lin Jr, MD, PhD27
1 Mayo Clinic, Rochester, United States
2 Mayo Clinic, Rochester, United States
3 Mayo Clinic, Rochester, United States
4 Mayo Clinic, Rochester, United States
5 Mayo Clinic, Rochester, United States
6 Mayo Clinic, Rochester, United States
7 Mayo Clinic, Rochester, United States
8 Mayo Clinic, Jacksonville, Florida, United States
9 Mayo Clinic, Rochester, United States
10 Mayo Clinic, Rochester, United States
11 Mayo Clinic, Rochester, United States
12 Mayo Clinic, Rochester, United States
13 Mayo Clinic, Rochester, United States
14 Mayo Clinic, Rochester, United States
15 Mayo Clinic, Rochester, United States
16 Mayo Clinic, Rochester, United States
17 Mayo Clinic, Rochester, United States
18 Mayo Clinic, Phoenix, Arizona, United States
19 Mayo Clinic, Phoenix, Arizona, United States
20 Mayo Clinic, Phoenix, Arizona, United States
21 Mayo Clinic, Phoenix, Arizona, United States
22 Mayo Clinic, Rochester, United States
23 Mayo Clinic, Rochester, United States
24 Mayo Clinic, Phoenix, Arizona, United States
25 Mayo Clinic, Jacksonville, Florida, United States
26 Mayo Clinic, Rochester, United States
27 Mayo Clinic, Rochester, United States

Randomized controlled study data in both CAR-T and bispecific antibodies (BsAb) demonstrate remarkable response rates and progression-free survival (PFS) and these therapies are now available in earlier lines of therapy (LOT) in multiple myeloma (MM). Given the differences in logistics and toxicities, predictive tools for either therapy at the time of evaluation can help inform therapy selection. SCOPE-MM (Rejeski et al., IMS 2025) uses pre-leukapheresis clinical variable to predict outcomes in patients (pts) receiving CAR-T; among 1,741 pts treated, the median (m)PFS for low, intermediate and high-risk SCOPE-MM scores were 18.6, 12.8 and 6.0 months (mo), respectively. CHARGE (Zanwar et al., ASH 2025/unpublished) predicts outcomes to BCMA- and GPRC5D-targeting BsAb. Prior analysis of 943 pts had the mPFS for low, intermediate and high-risk scores at 21.8, 7.1, and 1.6 mo, respectively. In pts who received Cilta-cel, we examined concordance and discordance of SCOPE-MM and CHARGE at time of evaluation and performance of SCOPE-MM, including patients in earlier LOT.

Pts treated with Cilta-cel at 3 Mayo Clinic sites (MN, AZ, FL) were included. Both scores were computed from pre-apheresis evaluation. SCOPE-MM assigns 2 points each for CAR-HEMATOTOX score≥3 and prior BCMA-directed therapy, and 1 point each for bone marrow plasma cells ≥50%, extramedullary disease, and LDH≥ULN (risk category: low 0, intermediate 1-2, high 3-7). CHARGE assigns 1 point each for del(17p) or ≥2 high-risk cytogenetic abnormalities, ferritin≥600 ng/mL, hemoglobin<9 g/dL, functional high-risk disease defined as relapse<18 mo from frontline therapy, ECOG≥2, and prior BCMA-directed therapy (risk categories: low 0-1, intermediate 2-3, high 4-6). PFS was calculated from Cilta-cel infusion to progression or death using Kaplan-Meier estimates.

Among 272 pts who received Cilta-cel in 2022-2025, SCOPE-MM was computable in 215/272 (79.0%), CHARGE in 201/272 (73.9%) and both in 144/272 (52.9%). Median follow-up was 21 mo (95% CI 18.7 to 23.9), with 93 progression or death events to date.

For SCOPE-MM, actual mPFS was not reached (NR) at low or intermediate risk, and 15 months (95% CI 9.3 to NR) at high risk. Each additional SCOPE-MM point was associated with shorter PFS (hazard ratio [HR] 1.42, 95% CI 1.24 to 1.63); intermediate (HR 1.73, 95% CI 0.98 to 3.05) and high-risk (HR 3.76, 95% CI 2.13 to 6.64) had inferior PFS compared to low-risk. This discrimination was confirmed in the subset not previously used for score development (n= 148/215; low-risk: mPFS NR, intermediate-risk: NR, high-risk: 17 months).

With limitation of a smaller sample size, discrimination of actual PFS showed inferior outcome for high risk category at 1-3 prior (p)LOT (15 mo vs. NR for low and intermediate, log-rank p=0.004) and ≥4 pLOT (mPFS NR for low, 32 mo (95% CI: 20 to NR) for intermediate, 20 mo (95% CI 6.3 to NR) for high risk).

Among the 144 pts with both scores available, risk categories were similar for only 49.3% (71/144) pts. Among the 59 pts with low risk SCOPE-MM score, 89.8% (53/59) also had low risk CHARGE score, 10.2% (6/59) had intermediate; among intermediate SCOPE-MM score, 61.2% (30/49) had low risk CHARGE score, 6.1% (3/49) had high risk CHARGE scores; and among high risk SCOPE-MM score, 30.6% (11/36) and 63.9% (23/36) had low-risk and intermediate risk CHARGE scores, respectively, with only 5.6% (2/36) also classified high risk.

The analysis will be expanded with additional patients and longer follow-up.

Both CAR-T and BsAb are now approved after one prior line of therapy, so selection between them is a routine decision in MM that may be supported by predictive tools. Both SCOPE-MM and CHARGE were computable using clinically accessible pre-leukapheresis data at Cilta-Cel evaluation. SCOPE-MM continues to predict CAR-T outcome in contemporary practice; also in 1-3 pLOT. Agreement on risk category was only 49.3% between CHARGE and SCOPE-MM, suggesting opportunity to examine predictors for patients who may have differential outcomes to CAR-T vs BsAb therapies. Larger cohorts and prospective evaluation are needed.

Christoph Schaefers, MD: Abbvie, Astra Zeneca, GSK, Janssen-Cilag, Sanofi, Takeda - Honoraria; Abbvie, Astra Zeneca, GSK, Janssen-Cilag, Sanofi, Takeda - Honoraria; Astra Zeneca, GSK, Janssen-Cilag, Menarini Stemline, oncopeptides, Pfizer, Regeneron - Consultancy (Includes expert testimony); Astra Zeneca, GSK, Janssen-Cilag, Menarini Stemline, oncopeptides, Pfizer, Regeneron - Consultancy (Includes expert testimony)